Paratek Pharmaceuticals Inc (PRTK)

Overview

Paratek Pharmaceuticals, Inc., a biopharmaceutical company, is based in Boston, Massachusetts, and was established in 1996. The company's primary focus is on the commercialization of vital medical treatments intended to combat severe illnesses and address significant public health crises. Their products serve civilian, governmental, and military markets, demonstrating a commitment to developing effective and innovative therapies. Paratek's mission is centered around delivering crucial healthcare solutions to patients through advanced science and strategic partnerships.

Products and Services

• NUZYRA

  NUZYRA is a comprehensive, once-daily antibiotic available in both oral and intravenous forms. It is designed for adult patients suffering from community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections that are caused by susceptible pathogens. This flagship medication reflects Paratek's commitment to addressing complex bacterial infections with effective treatment options.

• SEYSARA

  SEYSARA is a medication belonging to the tetracycline class, specifically formulated to treat moderate to severe cases of acne vulgaris. This product exemplifies Paratek's focus on developing targeted therapies that cater to the diverse needs of patients, providing them with options to manage challenging dermatological conditions.

• Collaboration and Licensing Agreements

  Paratek maintains strategic alliances with organizations such as Zai Lab (Shanghai) Co., Ltd. and Allergan plc to enhance its research and product development capabilities. These collaborative efforts enable Paratek to leverage external expertise and resources to strengthen its product offerings and reach broader markets.

• Tufts University License

  The company holds a license from Tufts University which empowers Paratek to develop and commercialize solutions targeted at bacterial or microbial diseases. This partnership underscores the company's commitment to cutting-edge research and development in the field of infectious diseases.

• BARDA Contract

  Paratek has secured a significant contract with the Biomedical Advanced Research and Development Authority (BARDA) aimed at advancing the application of NUZYRA for the treatment of pulmonary anthrax. This initiative highlights the company's role in addressing critical public health challenges and contributing to national preparedness against biothreats.

• XERAVATM License with Tetraphase Pharmaceuticals

  Paratek has a licensing agreement with Tetraphase Pharmaceuticals, Inc., granting it oversight of the development, import, and sale of XERAVATM. This product is utilized for complicated intra-abdominal infections of bacterial origin, further expanding the therapeutic options available to healthcare providers tackling serious infections.